RetaMaps

Maris Davis, M.D.

Maris Davis, M.D. · 123 HIGHLAND AVE · Glen Ridge, NJ 07028

4.7· 111 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Maris Davis, MD, is a physician with a practice in Glen Ridge, New Jersey, whose listing links to the website of Mountainside Medical Center, a community hospital that says it has served Montclair and surrounding communities since 1891. Telehealth visits are available. The Google profile shows 4.7 stars across 111 reviews dating to 2020, 30 in the past year, with reviewers most often mentioning the provider's knowledge (24 reviews) and the staff (22), then a caring manner and wait times.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice website—
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.7
Google rating · 111 reviews
30
reviews in the past year (avg ★ 4.9)
1
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2026-08-07. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.7 across 111 Google reviews. Of the 100 reviews we analyzed, 93 (93%) are positive (4–5★) and 5 (5%) are negative (1–2★).

What patients like

  • Knowledgeable, professional providers21 reviews
  • Friendly, helpful staff17 reviews
  • Feeling listened to12 reviews
  • Short waits, on-time visits7 reviews

Common complaints

  • Staff or front-desk issues4 of 5 negative
  • Felt rushed or unheard2 of 5 negative
5★
91
4★
2
3★
2
2★
3
1★
2

Most recent Google reviews

Carmen M.★★★★★2026-08-07

Polite, professional staff. Dr Davis is wonderful and easy to talk to. I have never had a bad experience in this office. I highly recommend.

Marianne N.★★★★★2026-07-16

As always, informative and professional.

James E.★★★★★2026-06-09

I've been seeing Dr. Davis for ~15 years. She's a great doctor. Empathetic, thorough, spends time with her patients.

Joe B.★★★★★2026-05-15

Dr Davis has been our mother‘s doctor for decades. She’s absolutely a wonderful doctor and a wonderful person. Takes great care of our mother. We trust her completely and recommend her highly.

Deedeefour85★★★★★2026-05-01

I’ve been to see dr Davis before and think she’s a great easy going dr. She took her time and was very thorough. The office is very clean. The staff is very friendly and the best part is you don’t have a long wait.

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Clinicians

  • Maris Davis, M.D.

Nearby providers in Glen Ridge

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs